Epidemiology of hepatitis C virus infection in HIV-infected individuals

Area of Science:

• Hepatology
• Infectious Diseases
• Virology

Background:

• Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is common.
• HIV/HCV coinfection leads to accelerated liver disease progression and poorer treatment outcomes.
• HCV RNA levels are often higher in coinfected individuals, increasing transmission risk.

Purpose of the Study:

• To review the challenges in managing patients coinfected with HIV and HCV.
• To discuss the implications of drug-drug interactions between antiretroviral therapy (ART) and HCV treatment.
• To highlight the impact of coinfection on liver disease progression and treatment efficacy.

Main Methods:

• Literature review of studies on HIV/HCV coinfection.
• Analysis of clinical data regarding disease progression and treatment responses.
• Examination of pharmacokinetic and pharmacodynamic interactions between ART and direct-acting antivirals (DAAs) or peginterferon/ribavirin.

Main Results:

• HIV/HCV coinfection is associated with more rapid fibrosis and cirrhosis development.
• Sustained virological response rates to HCV treatment are generally lower in coinfected patients.
• Significant drug-drug interactions can occur between ART and HCV treatment regimens, affecting efficacy and toxicity.

Conclusions:

• Effective management of HIV/HCV coinfection requires careful consideration of disease progression and treatment interactions.
• Optimizing treatment strategies is crucial to improve outcomes and reduce liver-related morbidity and mortality.
• Further research is needed to develop safer and more effective treatment protocols for coinfected individuals.